Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cogent Biosciences Q3 2026 Results: Net Loss of $111M, Loss Widens

Cogent Biosciences reported a net loss of $305.2 million for the nine months ended September 30, 2026, compared to $226.4 million in the prior year period, driven by increased R&D and G&A expenses. The company maintained a strong liquidity position with $791.1 million in cash, cash equivalents, and short-term marketable securities as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-111.4-80.9
EPS (diluted, $ a share)$-0.59$-0.50

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: COGT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cogent Biosciences, Inc.: key numbers

Share price
$27.44Close, Nov 16
Market cap
$4.77B
Shares outstanding
173.99MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cogent Biosciences, Inc.

All →
4:23 PM ET 8-K
Financial Results

Cogent Biosciences Financial Results

Cogent Biosciences reported third quarter 2026 financial results and provided a business update, highlighting a cash balance of $791.1 million which is expected to fund operations into late 2028. The company is preparing for the anticipated commercial launch of bezuclastinib in GIST with a PDUFA action date of November 30, 2026, and expects to file INDs for its JAK2 and KRAS pipeline programs in Q4 2026.

“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST. In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases.”

Andrew Robbins, Cogent’s President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.